Which companies overlap with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Eli Lilly and Company, Merck Sharp & Dohme LLC, AstraZeneca, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/johnson-johnson-pharmaceutical-research-development-l-l-c.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — Portfolio Competitive Intelligence Brief

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline: 11 marketed, 0 filed, 25 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 25 Phase 3 13 Phase 2 28 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ULTRAM ER	ULTRAM ER	marketed
Risperidone high dose	Risperidone high dose	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor	Psychiatry/Neurology
risperidone, quetiapine	risperidone, quetiapine	marketed
Pentosan polysulfate sodium 100 mg	Pentosan polysulfate sodium 100 mg	marketed
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor	Contraception / Reproductive Health
Risperidone low dose	Risperidone low dose	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor	Psychiatry
Abilify	Abilify	marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	Neuroscience
Other atypical antipsychotic drugs	Other atypical antipsychotic drugs	marketed
levofloxacin; metronidazole	levofloxacin; metronidazole	marketed	Fluoroquinolone + Nitroimidazole combination antibiotic	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole)	Infectious Disease
Paliperidone ER	Paliperidone ER	marketed
Yondelis	Yondelis	marketed		Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2	Oncology
CG 5503;tapentadol	CG 5503;tapentadol	phase 3	Opioid analgesic with norepinephrine reuptake inhibition	Mu-opioid receptor; norepinephrine transporter	Pain Management

Therapeutic area mix

Neurology · 5
Psychiatry · 4
Oncology · 3
Diabetes · 3
Women's Health · 2
Hematology · 2
Pain Management · 2
Gastrointestinal · 2
Other · 1
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Eli Lilly and Company · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Pfizer · 3 shared drug classes
Eisai Co., Ltd. · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Ain Shams University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Cite this brief

Drug Landscape (2026). Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/johnson-johnson-pharmaceutical-research-development-l-l-c. Accessed 2026-05-16.